Isagani "Izzy" Cornelio
About Isagani "Izzy" Cornelio
Isagani 'Izzy' Cornelio serves as the Vice President of Clinical Operations at Day One Biopharmaceuticals, a position he has held since 2020. He has extensive experience in the pharmaceutical industry, having previously worked in various leadership roles at companies such as Amgen, Exelixis, Merck, and Rainier Therapeutics.
Current Role at Day One Biopharmaceuticals
Isagani Cornelio serves as the Vice President of Clinical Operations at Day One Biopharmaceuticals. He has held this position since 2020, contributing to the company's focus on developing innovative therapies for patients with cancer. His role involves overseeing clinical trial operations and ensuring compliance with regulatory standards. He is based in South San Francisco, California.
Previous Experience in Clinical Operations
Prior to his current role, Cornelio held several significant positions in clinical operations. He was the Vice President of Clinical Operations at Rainier Therapeutics from 2017 to 2018. Before that, he served as Executive Director of Clinical Operations at Exelixis from 2013 to 2017. His experience also includes a tenure as Director of Medical Research at Amgen from 2000 to 2007 and a consulting role at Merck in 2019.
Educational Background
Isagani Cornelio studied at Cornell University, where he gained foundational knowledge in his field. He also attended the University of California, Los Angeles, further enhancing his expertise in clinical research and operations. His educational background supports his extensive career in the biopharmaceutical industry.
Career Timeline and Locations
Cornelio's career spans multiple organizations and roles within the biopharmaceutical sector. He worked at Amgen in Thousand Oaks, California, and held positions at Exelixis in Alameda, California, and Rainier Therapeutics in San Leandro, California. His consulting role at Merck took place in South San Francisco, California. This diverse experience has contributed to his current leadership role.